Mayo Clinic Q & amp;A podcast: Onco-regeneration -- Restoring function after a soft tissue cancer diagnosis
Soft tissue sarcoma is a rare form of cancer that has typically been treated using limb salvage surgery combined with radiation therapy. While limb salvage surgery helps patients avoid amputation, patients are often left with substantial functional limitations. Now advancements in microsurgery are making it possible to harness the body's ability to regenerate muscle strength after surgery to remove soft tissue sarcoma. Mayo Clinic orthopedic oncologists are teaming up with plastic surgeons in a procedure… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 8, 2021 Category: Databases & Libraries Source Type: news

ASTRO Issues Guideline on RT for Soft Tissue Sarcoma in Adults
Multidisciplinary evaluation recommended for all cases of STS; when indicated, preoperative RT recommended over postoperative RT (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 13, 2021 Category: Cancer & Oncology Tags: Oncology, Radiology, Surgery, Journal, Source Type: news

ASTRO Issues Guideline on RT for Soft Tissue Sarcoma in Adults
FRIDAY, Aug. 13, 2021 -- In a new clinical practice guideline from the American Society for Radiation Oncology (ASTRO), published online July 25 in Practical Radiation Oncology, evidence-based recommendations are presented for the use of radiation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2021 Category: Pharmaceuticals Source Type: news

Mayo Clinic Q & amp;A podcast: Be aware of the rare cancer called sarcoma
A sarcoma is a rare form of cancer that begins in the bones and in the softer connective tissues in the body. Sarcomas that begin in the bones are called "bone cancer," and sarcomas that form in the tissues, including muscle, fat, blood vessels, nerves, tendons, and the lining of joints, are called "soft tissue sarcoma." "These are rare cancers, and in adults, sarcomas comprise less than 1% of new cancers diagnosed every year," says… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 12, 2021 Category: Databases & Libraries Source Type: news

GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Globally regarded soft tissue sarcoma therapy has been approved by the Therapeutic Goods Administration for Australian patients YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SING... Biopharmaceuticals, Oncology, Regulatory Specialised Therapeutics Asia, YONDELIS, trabectedin, liposarcoma, leiomyosarcom (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 23, 2021 Category: Pharmaceuticals Source Type: news

Consumer Health: Treating sarcoma
Sarcoma is the general term for a broad group of cancers that begin in the bones and soft tissues. Soft tissue sarcoma forms in the tissues that connect, support and surround other body structures. This includes muscle, fat, blood vessels, nerves, tendons and the lining of your joints. There are more than 70 types of [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 5, 2021 Category: Databases & Libraries Source Type: news

Science Saturday: Regenerating muscles after cancer surgery
Advancements in microsurgery are making it possible to harness the body's healing power to regenerate muscle strength after some cancer surgeries, particularly surgery to remove soft tissue sarcoma. Mayo Clinic orthopedic oncologists are teaming with plastic surgeons in a procedure they've coined "oncoregeneration." They are seeking to perfect this procedure in which large muscle is transferred to close [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 18, 2020 Category: Databases & Libraries Source Type: news

Few High-Grade Soft Tissue Sarcoma Patients Receive Chemo
THURSDAY, Sept. 10, 2020 -- The rates of adults with high-grade soft tissue sarcoma (STS) who receive chemotherapy may be lower than expected, indicating a need for more aggressive systemic treatments, according to a study published in the August... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2020 Category: Pharmaceuticals Source Type: news

Chemotherapy is used to treat less than 25% of people with localized sarcoma
FINDINGSUCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone. In a nationwide analysis of nearly 20,000 patients whose cancer had not yet spread to other organs, the scientists learned that only 22% were treated with some form of chemotherapy.The researchers found that even among patients with the largest and most aggressive tumors, less than half (45%) received chemotherapy. The team also found that patients were more likely to be treated with chemotherapy at facilities that perform at least 55 surgeries for sarcom...
Source: UCLA Newsroom: Health Sciences - August 6, 2020 Category: Universities & Medical Training Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
In this study at UCLA, a national leader in the care of patients with sarcoma, researchers used a condensed five-day radiation regimen that considerably cuts down the length of treatment and the time to surgery.“Shortening the radiation therapy from five weeks to five days has been a very meaningful change for patients,” said lead author Dr. Anusha Kalbasi, assistant professor of radiation oncology in the division of molecular and cellular oncology. “Five weeks of daily treatments is a burdensome com mitment for patients. The daily back-and-forth can be expensive and time consuming, and it can really inte...
Source: UCLA Newsroom: Health Sciences - February 13, 2020 Category: Universities & Medical Training Source Type: news

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
(University of California - Los Angeles Health Sciences) A new study led by researchers at UCLA found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

Tazverik Approved to Treat Metastatic, Locally Advanced Epithelioid Sarcoma
Approval marks the first for a drug to treat this rare soft tissue sarcoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 25, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

B cells: New allies in sarcoma immunotherapy?
(INSERM (Institut national de la sant é et de la recherche m é dicale)) How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer? An international team led by Wolf Herv é Fridman with researchers from Inserm, Sorbonne Universit é and Universit é de Paris, has shown that B cells also play a major role in predicting of patient's response to immunotherapy. Their findings, to be published in Nature, pave the way for the personalization of treatments for patients with soft tissue sarcomas. (Source: EurekAlert! ...
Source: EurekAlert! - Medicine and Health - January 15, 2020 Category: International Medicine & Public Health Source Type: news

Public Insurance Tied to Lower Cancer Survival in Young Patients
FRIDAY, Dec. 27, 2019 -- Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 15 in Cancer Medicine. Neela L.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2019 Category: Pharmaceuticals Source Type: news

Markedly Elevated Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Markedly Elevated Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma
The risk of bone and soft-tissue sarcoma is markedly elevated in long-term survivors of hereditary retinoblastoma treated with radiation, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 26, 2019 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

Turning key metabolic process back on could make sarcoma more susceptible to treatment
(University of Pennsylvania School of Medicine) Soft tissue sarcoma cells stop a key metabolic process which allows them to multiply and spread, and so restarting that process could leave these cancers vulnerable to a variety of treatments (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 26, 2019 Category: Biology Source Type: news

Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast Neoadjuvant Chemotherapy for Primary Sarcoma of the Breast
This case suggests that breast sarcomas could be treated in the same way as other soft tissue sarcomas in terms of adjuvant chemotherapy.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 20, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Chest X-Ray Favored for Lung Surveillance After High-Grade Soft Tissue Sarcoma Chest X-Ray Favored for Lung Surveillance After High-Grade Soft Tissue Sarcoma
Chest x-ray may be better than chest CT for lung surveillance after resection of high-grade soft-tissue sarcoma, according to findings from the U.S. Sarcoma Collaborative (USSC).Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 3, 2019 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Complete Tumor Removal in Dogs Cuts Risk of Cancer's Return: Study
MONDAY, May 20, 2019 -- In dogs, soft tissue sarcoma is a group of malignant cancers that come from skin or connective tissue. Now, a new research review says when a tumor is completely removed, the risk of cancer returning is cut by nearly... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 20, 2019 Category: General Medicine Source Type: news

Cancer-stricken woman, 27, desperately tries to raise £500,000 for experimental treatment in the US
Hope Stringer, from Essex, is facing soft tissue sarcoma for the third time in five years. She was told the cancer had returned and spread weeks after she became engaged. (Source: the Mail online | Health)
Source: the Mail online | Health - February 11, 2019 Category: Consumer Health News Source Type: news

Olaratumab for Sarcoma Under Review After Negative Trial Olaratumab for Sarcoma Under Review After Negative Trial
The product has been used in combination with doxorubicin in patients with soft tissue sarcoma, but negative results from a confirmatory trial put its future in question.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

After winning accelerated approval, Lilly ’s cancer drug fails in study
An Eli Lilly treatment for advanced soft-tissue sarcoma missed the mark in a phase 3 study and will no longer be prescribed. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 21, 2019 Category: Pharmaceuticals Source Type: news

Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population. There were no new safety sign... Biopharmaceuticals, Oncology Eli Lilly, LARTRUVO, olaratumab, soft tissue sarcoma, leiomyosarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2019 Category: Pharmaceuticals Source Type: news

Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma
Molecularly targeted therapy and immunotherapy are changing the treatment landscape of soft tissue sarcoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical need for decades. A single oncogenic fusion gene is associated with treatment resistance and a 40 to 45% decrease in overall survival. We previously showed that expression of this PAX3:FOXO1 fusion oncogene in alveolar RMS (aRMS) mediates tolerance to chemotherapy and radiotherapy and that the class I–specific histone deacetylase (HDAC) inhibitor entinostat reduces PAX3:FOXO1 protein abundance. Here, we established the antitumor efficacy of entinostat with chemotherapy in various preclinical cell and mouse models and fou...
Source: Signal Transduction Knowledge Environment - November 20, 2018 Category: Science Authors: Bharathy, N., Berlow, N. E., Wang, E., Abraham, J., Settelmeyer, T. P., Hooper, J. E., Svalina, M. N., Ishikawa, Y., Zientek, K., Bajwa, Z., Goros, M. W., Hernandez, B. S., Wolff, J. E., Rudek, M. A., Xu, L., Anders, N. M., Pal, R., Harrold, A. P., Davies Tags: STKE Research Articles Source Type: news

Efficacy of Trabectedin in Elderly Patients With Sarcoma Efficacy of Trabectedin in Elderly Patients With Sarcoma
Elderly patients with good performance status benefit from trabectedin for soft tissue sarcoma similarly to younger patients.Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma
Trabectedin and eribulin are showing promise for the treatment of soft tissue sarcoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Big, Fat Tumors: Liposarcomas Can Top 70 Pounds
Sarcomas in the soft tissues (such as fat, nerves, ligaments, muscles) of all types are rare, accounting for less than 1% of all malignant tumors in adults. In 2018, the American Cancer Society estimates, about 13,000 new soft-tissue sarcomas of all types will be diagnosed, and about 5,000 Americans will die of them. (Source: WebMD Health)
Source: WebMD Health - October 5, 2018 Category: Consumer Health News Source Type: news

PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
TAIPEI, Taiwan, June 21, 2018 -- (Healthcare Sales & Marketing Network) -- PharmaEngine Inc. (TWO: 4162) and its corporate partner, Nanobiotix S.A. (Euronext: NANO) announced today that PEP503 (NBTXR3) in combination with radiotherapy met the primary endp... Biopharmaceuticals, Oncology PharmaEngine, Nanobiotix, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 22, 2018 Category: Pharmaceuticals Source Type: news

CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient, Doxil, Velcade and Benlysta LOS ANGELES, May 3, 2018 -- (Healthcare Sales & Marketing Network... Biopharmaceuticals, Oncology, Personnel CytRx, aldoxorubicin, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 3, 2018 Category: Pharmaceuticals Source Type: news

Crizotinib: New Standard for ALK+ Myofibroblastic Tumor Crizotinib: New Standard for ALK+ Myofibroblastic Tumor
With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor -- a very rare type of soft tissue sarcoma -- crizotinib should be the standard of care, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adult Soft Tissue Sarcoma
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 29, 2018 Category: General Medicine Source Type: news

First-Line Doxorubicin for Advanced Sarcoma, Not Combo? First-Line Doxorubicin for Advanced Sarcoma, Not Combo?
Doxorubicin should remain first-line therapy for patients with soft-tissue sarcoma, conclude trialists who compared it with a gemcitabine and docetaxel combination.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New clinical trial explores combining immunotherapy and radiation for sarcoma patients
(University of Maryland Medical Center) University of Maryland School of Medicine researchers are investigating a new approach to treat high-risk soft-tissue sarcomas by combining two immunotherapy drugs with radiation therapy to stimulate the immune system to destroy the main tumor as well as leftover microscopic cancer cells that may seed other tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

NantCell takes on troubled CytRx chemotherapeutic
NantCell, one of controversial biotech entrepreneur Patrick Soon-Shiong’s many businesses, said last week that it inked a deal to acquire CytRx‘s (NSDQ:CYTR) aldoxorubicin cancer drug. The compound has faced several obstacles in clinical trials, including when it missed the primary endpoint of a late-stage clinical trial, failing to help patients with second-line soft tissue sarcoma in a significant way compared to a control therapy. Get the full story at our sister site, Drug Delivery Business News. The post NantCell takes on troubled CytRx chemotherapeutic appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Biotech Drug-Device Combinations Mergers & Acquisitions Oncology Pharmaceuticals Wall Street Beat cytrx nantcell Source Type: news

Aldoxorubicin Shows Promise in Advanced Soft-Tissue Sarcoma
In this interview we discuss the phase III trial of aldoxorubicin in patients with advanced soft-tissue sarcoma, which showed improved efficacy and reduced toxicity over doxorubicin. (Source: CancerNetwork)
Source: CancerNetwork - July 22, 2017 Category: Cancer & Oncology Authors: Sant P. Chawla, MD Tags: Sarcoma Source Type: news

Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news

Coughing and constipation? You could be suffering from THIS rare whole-body cancer
COUGHING and constipation are two of the symptoms of soft tissue sarcomas - a group of rare cancers that can appear anywhere in the body. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2017 Category: Consumer Health News Source Type: news

Soft Tissue Sarcoma Differences: Therapeutic Implications Soft Tissue Sarcoma Differences: Therapeutic Implications
Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors, researchers report.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - May 4, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Development Program Can Support Approval, No New Studies Requested NDA Submission by CytRx Being Prepared Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT LOS ANGELES, April 19, 2017 -- (Healthcare Sales & Marketing Network) -- CytRx... Biopharmaceuticals, Oncology, FDA CytRx, aldoxorubicin, soft tissue sarcoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2017 Category: Pharmaceuticals Source Type: news

Saving Arms and Legs in Advanced Soft Tissue Sarcomas Saving Arms and Legs in Advanced Soft Tissue Sarcomas
In patients with soft tissue sarcoma facing amputation of an arm or a leg, regional chemotherapy with isolated limb infusion treats local disease without affecting survival.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 22, 2017 Category: Orthopaedics Tags: Hematology-Oncology News Source Type: news

A 5-Question Quiz on Sarcoma
Are you up to date on adverse prognostic factors for Ewing sarcoma? Do you know the latest drug approved for metastatic soft-tissue sarcoma? Test your knowledge on sarcoma in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - February 5, 2017 Category: Cancer & Oncology Authors: Debra Hughes Tags: Quiz Source Type: news

Common heart drug repurposed to treat rare cancer in Europe
A drug that's commonly used to treat high blood pressure is being repurposed for a rare tissue cancer in Europe. The medication, named propranolol, was recently granted Orphan Drug Designation by the European Commission (EC). The designation signifies that the EC supports the use of a drug to treat patients because of its significant benefit to those living with a rare disease - in this case, soft tissue sarcoma. (Source: World Pharma News)
Source: World Pharma News - January 17, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New Cancer Drug Approvals From 2016
Chemotherapy is one of the most powerful tools we have to treat cancer, and research continues to find new chemotherapy drugs as well as new uses for existing ones. At the same time, newer types of drugs are continually being developed that work in different ways to attack cancer cells.They include targeted therapy, which aims to more precisely identify cancer cells while doing less damage to normal cells, and immunotherapy, which uses the body’s own immune system to help find and destroy cancer.Before any new drug can be sold in the United States, it has to go through an approval process by the Food and Drug Adminis...
Source: American Cancer Society :: News and Features - December 26, 2016 Category: Cancer & Oncology Tags: Advanced Cancer Source Type: news

Combo of cancer drugs shows promise against some tumors
HealthDay News Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 2, 2016 Category: Consumer Health News Source Type: news

Drug Combo Shows Promise Against Some Soft Tissue Tumors
FRIDAY, Dec. 2, 2016 -- Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 2, 2016 Category: Journals (General) Source Type: news

Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 2, 2016 Category: Science Source Type: news

Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
(ECCO-the European CanCer Organisation) Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news